Sign up


Match Document Document Title
7153509 Immunogenic peptides comprising a T-helper epitope and a B-cell neutralizing antibody epitope  
The present invention relates, generally, to a polyvalent immunogen and, more particularly, to a method of inducing neutralizing antibodies against HIV and to a polyvalent immunogen suitable for...
7147849 Pharmaceutical formulation  
A pharmaceutical formulation containing at least one protein-containing substance and at least one substance selected from the group of compatible solutes.
7147862 Vaccine composition containing adjuvants  
The present invention provides vaccine compositions comprising 3 De-O-acylated monophosphoryl lipid A and QS21. The vaccines compositions are potent inducers of CTL and γ IFN responses.
7129334 Synthetic peptide and uses for same  
Beta taipoxin obtained the taipoxin component of the venom of the taipan snake, Oxyuranus s. scutellatus, was fragmented by trypsin digestion. The fragment which showed the highest activity on skin...
7125556 Nucleic acid molecule comprising a nucleic acid sequence coding for a haemocyanin  
A nucleic acid molecule or construct alone or with a promoter suitable for expression control is contemplated that codes for a haemocyanin, a haemocyanin domain or a fragment thereof with the...
7122191 Microfluidized oil-in-water emulsions and vaccine compositions  
This invention provides submicron oil-in-water emulsions useful as a vaccine adjuvant for enhancing the immunogenicity of antigens. The present invention also provides vaccine compositions...
7122192 Porcine circoviruses, vaccines and diagnostic reagents  
The invention relates to new porcine circovirus strains isolated from pulmonary or ganglionic samples obtained from farms affected by the post-weaning multisystemic wasting syndrome (PMWS). It...
7122620 Haptotactic peptides  
This invention is related to a novel peptide consisting of the amino acid sequence of SEQ ID NO:1, and a pharmaceutical composition comprising the peptide thereof.
7118749 Transferrin receptor genes  
Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic...
7118874 Immunogenic formulation and process for preparation thereof  
A process is disclosed for preparation of a immunogenic peptide mixture in a single synthesis. The peptide mixture collectively represents the in vivo variability seen in immunogenic epitopes from...
7115562 Peptides and their use to ameliorate cell death  
The present invention relates to a method of reducing cell death in a warm-blood animal wherein said cell death associated with a neurodegenerative disorder, an immune disease, a neoplastic...
7115579 Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides  
The invention provides methods for modulating the immune response caused by CpG dinucleotide-containing compounds. The methods according to the invention enables both decreasing the...
7115268 Peptides useful for reducing symptoms of toxic shock syndrome and septic shock  
This invention relates to compositions and methods which provide protection against, or reduce the severity of toxic shock and septic shock from bacterial infections. More particularly it relates...
7105162 Pharmaceutical composition for immunomodulation based on peptides and adjuvants  
Pharmaceutical composition containing at least one peptide or protein (fragment) with an immunomodulatory activity together with an adjuvant. The peptide is derived from a pathogenic agent or a...
7101560 Combination vaccine for administration to adolescents  
Novel combined vaccine compositions are provided, comprising a herpes simplex virus (HSV) antigen and a HPV antigen and optionally in addition one or more of the following: an EBV antigen, a...
7097837 Synthetic vaccine agents  
The present invention provides for novel immungens that are comprised of an activated polyhydroxypolymer backbone to which is attached 2 separate antigenic determinants. The 1st antigenic...
7094391 Compositions and methods for administering Borrelia burgdorferi antigens  
Mucosal administration of OspA and compositions therefor are disclosed and claimed. More particularly, oral administration of OspA and compositions therefor for eliciting an immunological response...
7094413 Combined therapy for treatment of HIV infection  
The present invention relates to pharmaceutical preparations and methods for treating individuals infected with the human immunodeficiency virus (HIV). The pharmaceutical preparations comprise an...
7090853 Noscapine derivatives as adjuvant compositions and methods of use thereof  
An adjuvant composition comprising noscapine and its derivatives, for use in the treatment of tumors, cancer, as an adjuvant for vaccines.
7087573 Methods of inhibiting platelet anti-HLA alloimmune antibody responses with soluble 18 KDa CD40L  
The invention relates to a method for inhibiting an in vivo alloimmune response, and to the use of a soluble recombinant human CD40L protein containing the active binding site with CD40. In...
7083798 Method of immunomodulatory treatment of insulin dependent diabetes mellitus using mycobacterial cell wall compositions  
The present invention relates generally to a method of immunomodulating therapy and pharmaceutical compositions useful for same. More particularly, the present invention provides a method of...
7083787 Yeast-dendritic cell vaccines and uses thereof  
Disclosed is a vaccine that includes a dendritic cell loaded with a yeast vehicle and antigen. Also disclosed are methods of making the vaccine and using the vaccine to elicit cellular and humoral...
7078388 DNA vaccines for farm animals, in particular bovines and porcines  
DNA vaccine against a pathogen affecting farm animals, in particular bovines or porcines, comprising a plasmid containing a nucleotide sequence encoding an immunogen of a pathogen of the animal...
7070781 Nontoxic mucosal adjuvant  
A non-toxic mucosal adjuvant is provided which may be admixed with further antigens to provide a vaccine administrable to mucosal surfaces in organisms including man. Preferably, the non-toxic...
7067139 Method for treating autoimmune diseases  
A method of treating patients having rheumatoid arthritis by administering Product R, a peptide-nucleic acid preparation, is disclosed.
7067639 Method to provide bacterial ghosts provided with antigens  
Methods for improving binding of a proteinaceous substance to cell-wall material of a Gram-positive bacterium are disclosed. The proteinaceous substance includes an AcmA cell-wall binding domain,...
7063854 Composition and methods for WTI specific immunotherapy  
Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an...
7060453 Method and kit for the determination of analyte concentration in blood  
A method is provided for determining the level of an analyte in the blood of an individual based on determination of the level of the same analyte in non-blood sample (e.g. urine, saliva and hair)...
7056521 Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants  
The present invention provides parenteral adjuvants comprising detoxified mutants of bacterial ADP-ribosylating toxins, particularly those from pertussis (PT), cholera (CT), and heat-labile E. coli...
7052701 Inactivated influenza virus vaccine for nasal or oral application  
The invention relates to nasal or oral administration of a compound containing inactivated influenza virus antigen and aluminum as adjuvant for the prophylaxis of influenza virus infections. Said...
7053176 Combination of C1-INH and lung surfactant for the treatment of respiratory disorders  
Pharmaceutical composition for the treatment of infant respiratory distress syndrome and acute lung injury (including adult respiratory distress syndrome) which contains C1 esterase inhibitor...
7048906 Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions  
Disclosed is a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject. SIBO-caused conditions include irritable bowel syndrome, fibromyalgia,...
7049302 Compositions of CPG and saponin adjuvants and uses thereof  
Vaccine compositions of immunostimulatory oligonucleotides and saponin adjuvants and antigens and the use thereof for stimulating immunity, enhancing cell-mediated immunity, and enhancing antibody...
7041301 Interferon immunotherapy  
A method for reducing the recurrence of a resectable malignant tumor includes administering an immunostimulatory dosage of an α-interferon composition, then surgically resecting the malignant ...
7041294 Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects  
A method of eliciting an immune response against an antigen in a vertebrate subject, the method comprising the steps of providing an antigen-adjuvant composition comprising the antigen and a...
7041302 Therapeutic modulation of the tumor inflammatory response  
The invention relates to compositions, kits, and methods for alleviating cancer (i.e., a tumor) in a human patient. The therapeutic modality effected by the invention involves inducing a type 1...
7037500 Method for using phagocytic particles and ATP receptors to deliver antigens to MHC class I receptors to induce immunity against microbial pathogens or tumors or to suppress immunity  
This invention provides methods of delivering an antigen to an Class I or Class II MHC receptors to induce immunity against the antigen in a subject having a disease. This invention also provides...
7037510 Hybrids of M. tuberculosis antigens  
The present invention discloses fusion proteins of the immunodominant antigens ESAT-6 and Ag85B from Mycobacterium tuberculosis or homologues thereof, and a tuberculosis vaccine based on the fusion...
7037501 Myostatin immnoconjugate  
A method to alter the phenotype of animals, e.g., avians, which employs passive and active immunization is provided.
7033591 Immunostimulant bacterial membrane fractions in cancer treatment  
The invention concerns the use of a membrane fraction of gram-negative bacteria, in particular Klebsiella pnemoniae for preparing a pharmaceutical composition that is immunostimulant and/or capable...
7029656 Methods and formulations for the efficient delivery of water-insoluble drugs by nebulizer  
Formulations, methods and devices for producing formulations and methods for nebulizer delivery of formulations of water-insoluble drugs are provided. Also provided are methods for minimizing...
7030219 B7-DC, Dendritic cell co-stimulatory molecules  
A novel costimulatory protein molecule, B7-DC, which is a member of the B7 family, is described as is DNA coding therefor and expression vectors comprising this DNA. B7-DC protein, fragments,...
7030094 Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and QS-21  
The invention provides pharmaceutical compositions, particularly vaccine compositions, employing an adjuvant system comprising RC-529 (an aminoalkyl glucosaminide phosphate compound) and QS-21 (a...
7026166 Fluorogenic dyes  
The present invention relates to the use of fluorogenic or chromogenic dyes as reporter molecules for detecting cell entry by a specific molecule.
7022496 Use of gene product of adenovirus early region 4 ORF-6 to inhibit repair of double-strand breaks in DNA  
The present invention provides a modified adenovirus comprising genomic adenoviral DNA which has been modified so that (i) the only gene product of the early region (E4) that is expressed is open...
7014856 Ganglioside-KLH conjugate vaccines plus OS-21  
This invention provides a vaccine for stimulating or enhancing in a subject to which the vaccine is administered, production of an antibody which recognizes a ganglioside, comprising an amount of...
7012129 Antiviral composition comprising glycine amide  
Embodiments relate to the discovery that certain tripeptide amides and glycine amide can be used to inhibit viral infection, including human immunodeficiency virus (HIV) infection. More...
7011836 Mutants of gram negative mucosal bacteria and application thereof in vaccines  
It is possible to inactivate the early stage of lipid A synthesis of mucosal gram negative bacteria without compromising cell viability. In particular the lpxA gene in N. meningitidis was mutated...
7001601 Ganglioside-KLH conjugate vaccine plus QS-21  
This invention provides a vaccine for stimulating or enhancing in a subject to which the vaccine is administered, production of an antibody which recognizes a ganglioside, comprising an amount of...
6987166 Compositions and methods for the treatment of sepsis  
The present invention relates to compositions and methods for the prevention and treatment of blood-borne and toxin mediated diseases, and in particular anti-C5a antibodies for the prevention and...